risedronic acid has been researched along with Body Weight in 18 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Retrospective single-center cohort study of osteoporosis patients treated with alendronate or risedronate for at least 2 years and then discontinued their bisphosphonate for a drug holiday." | 3.83 | Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. ( Adams-Huet, B; Maalouf, NM; Poindexter, JR; Xu, LH, 2016) |
| " Long-term use of bisphosphonates prevented reductions in BMI and body weight, usually observed in elderly women." | 1.48 | Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women. ( Inoue, S; Kuroda, T; Shiraki, M; Tanaka, S; Uenishi, K; Urano, F; Urano, T, 2018) |
| "The purpose of the present study was to examine the effect of pretreatment with risedronate and/or vitamin K2 and treatment continuation with reduced dosing frequency of the drugs on the early cancellous bone loss induced by ovariectomy (OVX) in rats." | 1.33 | Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study. ( Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006) |
| "The relationship between bone turnover and bone tissue and material properties was examined in ovariectomized (OVX) rats treated with risedronate in combination with or without vitamin K2." | 1.32 | Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2. ( Ikeda, S; Ito, M; Nakamura, T; Otomo, H; Phipps, RJ; Sakai, A; Tanaka, S, 2004) |
| " The study was designed as a dose-response study, and the site-specific effects of immobilization and of treatment are described." | 1.31 | Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. ( Mackey, MS; Mosekilde, L; Phipps, RJ; Thomsen, JS, 2000) |
| " These findings indicated that the long-term administration of PGE2 alone cannot maintain or continue to add bone mass in ovx rats but that co-treatment of a PGE2 with an anti-resorptive or activation agent can resist the influence of the mechanostat induced bone loss as well as continue to add bone." | 1.29 | Co-treatment of PGE2 and risedronate is better than PGE2 alone in the long-term treatment of ovariectomized-induced osteopenic rats. ( Chen, YY; Ijiri, K; Jee, WS; Ke, HZ; Ma, Y, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 10 (55.56) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Urano, T | 1 |
| Shiraki, M | 1 |
| Kuroda, T | 1 |
| Tanaka, S | 2 |
| Urano, F | 1 |
| Uenishi, K | 1 |
| Inoue, S | 1 |
| Xu, LH | 1 |
| Adams-Huet, B | 1 |
| Poindexter, JR | 1 |
| Maalouf, NM | 1 |
| Iwamoto, J | 4 |
| Matsumoto, H | 1 |
| Takeda, T | 4 |
| Sato, Y | 4 |
| Liu, X | 1 |
| Yeh, JK | 4 |
| Matsumoto, Y | 1 |
| Mikuni-Takagaki, Y | 1 |
| Kozai, Y | 1 |
| Miyagawa, K | 1 |
| Naruse, K | 1 |
| Wakao, H | 1 |
| Kawamata, R | 1 |
| Kashima, I | 1 |
| Sakurai, T | 1 |
| Fujita, Y | 1 |
| Watanabe, K | 1 |
| Uchikanbori, S | 1 |
| Maki, K | 1 |
| Sugiyama, T | 1 |
| Meakin, LB | 1 |
| Galea, GL | 1 |
| Jackson, BF | 1 |
| Lanyon, LE | 1 |
| Ebetino, FH | 1 |
| Russell, RG | 1 |
| Price, JS | 1 |
| Erben, RG | 1 |
| Mosekilde, L | 2 |
| Thomsen, JS | 2 |
| Weber, K | 1 |
| Stahr, K | 1 |
| Leyshon, A | 1 |
| Smith, SY | 1 |
| Phipps, R | 1 |
| Otomo, H | 1 |
| Sakai, A | 1 |
| Ikeda, S | 1 |
| Ito, M | 1 |
| Phipps, RJ | 3 |
| Nakamura, T | 1 |
| Seki, A | 2 |
| Yamada, H | 2 |
| Shen, CL | 2 |
| Fuchs, RK | 1 |
| Burr, DB | 1 |
| Jee, WS | 3 |
| Lin, BY | 1 |
| Ma, YF | 1 |
| Ke, HZ | 3 |
| Hall, DG | 1 |
| Stoica, G | 1 |
| Ma, Y | 1 |
| Chen, YY | 1 |
| Ijiri, K | 1 |
| Mackey, MS | 1 |
| Libouban, H | 1 |
| Moreau, MF | 1 |
| Legrand, E | 1 |
| Baslé, MF | 1 |
| Audran, M | 1 |
| Chappard, D | 1 |
| Tang, LY | 1 |
| Kimmel, DB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203] | Phase 2 | 120 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 other studies available for risedronic acid and Body Weight
| Article | Year |
|---|---|
Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women.
Topics: Aged; Alendronate; Asian People; Biomarkers; Body Composition; Body Mass Index; Body Weight; Bone De | 2018 |
Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Topics: Aged; Alendronate; Body Weight; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fema | 2016 |
Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Dru | 2008 |
Prior treatment with vitamin K(2) significantly improves the efficacy of risedronate.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Drug Administration Schedule; Drug Evaluatio | 2009 |
Effects of risedronate on cortical and trabecular bone of the mandible in glucocorticoid-treated growing rats.
Topics: Anatomy, Cross-Sectional; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Etid | 2011 |
Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice.
Topics: Animals; Body Weight; Bone and Bones; Etidronic Acid; Female; Fluorescent Dyes; Mice; Mice, Inbred C | 2011 |
Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha,25-dihydroxyvitamin D3.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone Density; Calcitriol; Etidronic Acid; Female; Ost | 2002 |
Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2.
Topics: Absorptiometry, Photon; Amino Acids; Animals; Biomechanical Phenomena; Body Weight; Bone Density; Bo | 2004 |
Comparative effects of risedronate and calcitriol on cancellous bone in rats with glucocorticoid-induced osteopenia.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metaboli | 2006 |
Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study.
Topics: Absorptiometry, Photon; Analysis of Variance; Animals; Body Weight; Bone Density; Bone Density Conse | 2006 |
Effect of risedronate on the cortical and cancellous bone mass and mechanical properties in ovariectomized rats: a comparison with the effects of alfacalcidol.
Topics: Analysis of Variance; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Res | 2006 |
Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.
Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Remodeling; | 2008 |
Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats.
Topics: Aging; Analysis of Variance; Animals; Body Weight; Bone Development; Bone Resorption; Calcium Channe | 1995 |
Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Body Weight; Bone and Bones; Bone Neoplasms; Bone Res | 1994 |
Co-treatment of PGE2 and risedronate is better than PGE2 alone in the long-term treatment of ovariectomized-induced osteopenic rats.
Topics: Aging; Animals; Body Weight; Bone Development; Bone Diseases, Metabolic; Dinoprostone; Drug Therapy, | 1995 |
Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats.
Topics: Alendronate; Animals; Body Weight; Etidronic Acid; Female; Femur; Hindlimb Suspension; Osteoporosis; | 2000 |
Comparison insight dual X-ray absorptiometry (DXA), histomorphometry, ash weight, and morphometric indices for bone evaluation in an animal model (the orchidectomized rat) of male osteoporosis.
Topics: Absorptiometry, Photon; Animals; Body Weight; Bone and Bones; Bone Density; Climacteric; Disease Mod | 2001 |
Restoring and maintaining bone in osteopenic female rat skeleton: I. Changes in bone mass and structure.
Topics: Aging; Animals; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Resorption | 1992 |